Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Toxic protein could explain Alzheimer’s and lead to breakthroughs

19.08.2003


Researchers at Northwestern University have discovered for the first time in humans the presence of a toxic protein that they believe to be responsible for the devastating memory loss found in individuals suffering from Alzheimer’s disease.



An understanding of this key molecular link in the progression of Alzheimer’s could lead to the development of new therapeutic drugs capable of reversing memory loss in patients who are treated early, in addition to preventing or delaying the disease. Help for individuals with pre-Alzheimer’s memory failure (mild cognitive impairment) also is envisioned. The findings will be published online by the Proceedings of the National Academy of Sciences during the week of Aug. 18.

The research team, led by William L. Klein, professor of neurobiology and physiology, found up to 70 times more small, soluble aggregated proteins called "amyloid b-derived diffusible ligands" (ADDLs, pronounced "addles") in the brain tissue of individuals with Alzheimer’s disease compared to that of normal individuals.


The clinical data strongly support a recent theory in which ADDLs accumulate at the beginning of Alzheimer’s disease and block memory function by a process predicted to be reversible. ADDLs have the ability to attack the memory-building activity of synapses, points of communication where neurons exchange information, without killing neurons.

"Researchers for more than a decade thought it was big molecules, the ’amyloid fibrils,’ that caused memory problems, but we think the real culprits are extremely small molecules, what we call ADDLs," said Klein, who is a member of Northwestern’s Cognitive Neurology and Alzheimer’s Disease Center. "Now we’ve shown that ADDLs are present in humans and are a clinically valid part of Alzheimer’s pathology. If we can develop drugs that target and neutralize these neurotoxins, it might be possible to not only slow down memory loss, but to actually reverse it, to bring memory function back to normal."

Although both are a form of amyloid beta, ADDLs and their properties differ significantly from the amyloid fibrils (known as plaques) that are a diagnostic hallmark of Alzheimer’s. ADDLs found in human brains, mostly 12 or 24 amyloid beta proteins clumped together, are tiny and undetectable in conventional neuropathology; fibrils are much, much larger. While fibrils are immobile toxic waste dumps, ADDLs are soluble and diffuse between brain cells until they find vulnerable synapses. (Single pieces of amyloid beta protein in the brain is normal.)

"The difference between ADDLs and fibrils is like comparing four eggs, over easy, to an enormous omelet that could feed the entire Chicago Bears team," said Klein. ""You start with eggs, but the final product taste, texture and size are all different."

The existence of ADDLs may help explain the poor correlation between plaques and neurological deficits. Studies by other researchers have shown a reversal of memory failure in mouse models treated with amyloid beta antibodies -- but without any reduction in plaque. The antibodies appear to restore memory because they neutralize ADDLs, which Klein’s group has found in mouse models with Alzheimer’s as well as in human brains with Alzheimer’s.

Klein’s research team recently began a study funded by the National Institutes of Health to continue investigating ADDLs in humans and further characterize these molecules. In addition to Alzheimer’s disease, ADDL-like molecules could be the cause of other degenerative diseases.

Klein also is working with researchers at Northwestern’s Institute for Nanotechnology on clinical diagnostics capable of detecting ADDLs in blood or cerebral spinal fluid. Currently diagnosis of Alzheimer’s is based primarily on a battery of psychological tests.

"Now that ADDLs have been discovered in humans we would like to develop effective diagnostics and that means employing nanotechnology," said Klein. "That’s because ADDLs are present in very low concentrations, and nanotechnology has the potential to provide the ultra-sensitive assays needed for the clinic."

Klein, Grant A. Krafft, formerly at Northwestern University Medical School and now chief scientific officer at Acumen Pharmaceuticals, Inc., and Caleb E. Finch, professor of biological sciences and gerontology at the University of Southern California, reported the discovery of ADDLs in 1998. Krafft and Finch are co-authors on the PNAS paper. Northwestern and USC hold joint patents on the composition and use of ADDLs in neurodisorders.

The patent rights have been licensed to Acumen Pharmaceuticals, based in Glenview, Ill., for the development of drugs that treat Alzheimer’s disease and other memory-related disorders. Clinical trials could be two or three years away.

In addition to Klein, Krafft and Finch, other authors on the paper are Yuesong Gong (lead author), Lei Chang, Kirsten L. Viola, Pascale N. Lacor and Mary P. Lambert, from Northwestern University.


The research was supported by the National Institutes of Health, the Boothroyd, Feiger and French foundations, and the Institute for the Study of Aging.

Megan Fellman | EurekAlert!
Further information:
http://www.nwu.edu/

More articles from Health and Medicine:

nachricht Illinois team develops first of a kind in-vitro 3D neural tissue model
11.12.2019 | University of Illinois College of Engineering

nachricht Safer viruses for vaccine research and diagnosis
11.12.2019 | University of Queensland

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Highly charged ion paves the way towards new physics

In a joint experimental and theoretical work performed at the Heidelberg Max Planck Institute for Nuclear Physics, an international team of physicists detected for the first time an orbital crossing in the highly charged ion Pr⁹⁺. Optical spectra were recorded employing an electron beam ion trap and analysed with the aid of atomic structure calculations. A proposed nHz-wide transition has been identified and its energy was determined with high precision. Theory predicts a very high sensitivity to new physics and extremely low susceptibility to external perturbations for this “clock line” making it a unique candidate for proposed precision studies.

Laser spectroscopy of neutral atoms and singly charged ions has reached astonishing precision by merit of a chain of technological advances during the past...

Im Focus: Ultrafast stimulated emission microscopy of single nanocrystals in Science

The ability to investigate the dynamics of single particle at the nano-scale and femtosecond level remained an unfathomed dream for years. It was not until the dawn of the 21st century that nanotechnology and femtoscience gradually merged together and the first ultrafast microscopy of individual quantum dots (QDs) and molecules was accomplished.

Ultrafast microscopy studies entirely rely on detecting nanoparticles or single molecules with luminescence techniques, which require efficient emitters to...

Im Focus: How to induce magnetism in graphene

Graphene, a two-dimensional structure made of carbon, is a material with excellent mechanical, electronic and optical properties. However, it did not seem suitable for magnetic applications. Together with international partners, Empa researchers have now succeeded in synthesizing a unique nanographene predicted in the 1970s, which conclusively demonstrates that carbon in very specific forms has magnetic properties that could permit future spintronic applications. The results have just been published in the renowned journal Nature Nanotechnology.

Depending on the shape and orientation of their edges, graphene nanostructures (also known as nanographenes) can have very different properties – for example,...

Im Focus: Electronic map reveals 'rules of the road' in superconductor

Band structure map exposes iron selenide's enigmatic electronic signature

Using a clever technique that causes unruly crystals of iron selenide to snap into alignment, Rice University physicists have drawn a detailed map that reveals...

Im Focus: Developing a digital twin

University of Texas and MIT researchers create virtual UAVs that can predict vehicle health, enable autonomous decision-making

In the not too distant future, we can expect to see our skies filled with unmanned aerial vehicles (UAVs) delivering packages, maybe even people, from location...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

The Future of Work

03.12.2019 | Event News

First International Conference on Agrophotovoltaics in August 2020

15.11.2019 | Event News

Laser Symposium on Electromobility in Aachen: trends for the mobility revolution

15.11.2019 | Event News

 
Latest News

Self-driving microrobots

11.12.2019 | Materials Sciences

Innovation boost for “learning factory”: European research project “SemI40” generates path-breaking findings

11.12.2019 | Information Technology

Molecular milk mayonnaise: How mouthfeel and microscopic properties are related in mayonnaise

11.12.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>